

November 29, 2016

MPH Mittelständische Pharma Holding AG:

Preliminary IFRS results for first 9 month 2016:

Net profit EUR 33.07 million (77 Cent per share) in first 9 month period 2016, thereof 31 Cent per share produced in third quarter, profit growth compared to prior quarter of 18%, equity EUR 166.95 million (3.90 EUR per share)

MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0L1H32), reports its preliminary IFRS Group results for the first 9 months 2016.

In the first 9 months 2016 the preliminary IFRS Group net profit amounted to EUR 33.07 million.

The investments listed on Frankfurt Stock Exchange, HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG performed successfully in the first 9 months 2016.

HAEMATO achieved in the first 9 months sales growth of 31.6% and net profit growth of 47.3%.

M1 Kliniken AG increases the utilised capacity on an ongoing basis in the Berlin clinic and the twelve M1-outpatient service centres throughout Germany.

CR Capital Real Estate AG benefits from progress in the project development in Leipzig area.

„The net income of EUR 13.19 million in the third quarter outperformed the net income of EUR 11.19 million in the second quarter by about 18%. This is a pleasant development considering that the net profit in the second quarter already outperformed the profit of EUR 8.69 million in the first quarter by 28.7%. We expect further profit growth in the fourth quarter 2016“, say Patrick Brenske und Dr. Christian Pahl, Members of the Management Board of MPH.

About MPH Mittelständische Pharma Holding AG:

MPH AG is an investment entity strategically focused on the purchase, development and sale of companies and shares in companies especially from the growth segments of the healthcare market. This includes insurance reimbursed segments as well as privately financed segments.

Kontakt:

MPH Mittelständische Pharma Holding AG
Susanne Seger
Grünauer Straße 5
D-12557 Berlin

Tel.: +49 (0) 30 897 30 86 60
Fax: +49 (0) 30 897 30 86 69

E-Mail: ir@mph-ag.de
Web: www.mph-ag.de

November 29, 2016

But also beyond the healthcare market MPH makes use of potentials of high growth areas.

Key figures for the share of MPH Mittelständische Pharma Holding AG:

Subscribed capital: EUR 42,813,842

Listed shares: ordinary shares

ISIN: DE000A0L1H32

WKN: A0L1H3

Stock symbol: 93M

Contact:

Susanne Seger

MPH Mittelständische Pharma Holding AG

Grünauer Straße 5

D-12557 Berlin

Phone: +49 (0) 30 897308660 Fax: +49 (0) 30 897308669

E-Mail: ir@mph-ag.de Web: www.mph-ag.de

Kontakt:

MPH Mittelständische Pharma Holding AG

Susanne Seger

Grünauer Straße 5

D-12557 Berlin

Tel.: +49 (0) 30 897 30 86 60

Fax: +49 (0) 30 897 30 86 69

E-Mail: ir@mph-ag.de

Web: www.mph-ag.de